PE20060678A1 - Formas cristalinas de derivados de etilamina y procedimiento de preparacion de los mismos - Google Patents
Formas cristalinas de derivados de etilamina y procedimiento de preparacion de los mismosInfo
- Publication number
- PE20060678A1 PE20060678A1 PE2005000372A PE2005000372A PE20060678A1 PE 20060678 A1 PE20060678 A1 PE 20060678A1 PE 2005000372 A PE2005000372 A PE 2005000372A PE 2005000372 A PE2005000372 A PE 2005000372A PE 20060678 A1 PE20060678 A1 PE 20060678A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- procedure
- preparation
- monoclorhydrate
- polymorph
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical class CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 2
- 230000001681 protective effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940121786 Beta 2 adrenoreceptor agonist Drugs 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- -1 HYDROXYL GROUP Chemical group 0.000 abstract 1
- 208000018569 Respiratory Tract disease Diseases 0.000 abstract 1
- 206010057190 Respiratory tract infections Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 238000005349 anion exchange Methods 0.000 abstract 1
- 229940125890 compound Ia Drugs 0.000 abstract 1
- 238000010511 deprotection reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005588 protonation Effects 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0407521A GB0407521D0 (en) | 2004-04-02 | 2004-04-02 | Chemical process |
| GB0411688A GB0411688D0 (en) | 2004-05-25 | 2004-05-25 | Chemical process |
| US57446704P | 2004-05-26 | 2004-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060678A1 true PE20060678A1 (es) | 2006-08-02 |
Family
ID=34963396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000372A PE20060678A1 (es) | 2004-04-02 | 2005-03-31 | Formas cristalinas de derivados de etilamina y procedimiento de preparacion de los mismos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7846973B2 (https=) |
| EP (1) | EP1730104A1 (https=) |
| JP (1) | JP2007530652A (https=) |
| AR (1) | AR052301A1 (https=) |
| AU (1) | AU2005227733A1 (https=) |
| BR (1) | BRPI0509382A (https=) |
| CA (1) | CA2561400A1 (https=) |
| IL (1) | IL178064A0 (https=) |
| MA (1) | MA28558B1 (https=) |
| NO (1) | NO20064884L (https=) |
| PE (1) | PE20060678A1 (https=) |
| TW (1) | TW200536814A (https=) |
| WO (1) | WO2005095328A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006066907A1 (en) * | 2004-12-21 | 2006-06-29 | Glaxo Group Limited | Pharmaceutical formulations |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| AU2009203693B2 (en) | 2008-01-11 | 2012-06-07 | Novartis Ag | Pyrimidines as kinase inhibitors |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| IT1399912B1 (it) * | 2010-04-29 | 2013-05-09 | Lundbeck Pharmaceuticals Italy S Pa | Processo di preparazione di ritodrina cloridrato. |
| JP5645762B2 (ja) * | 2010-06-29 | 2014-12-24 | 日本ポリプロ株式会社 | ポリオレフィンの結晶性分布分析方法およびその装置 |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| MA34969B1 (fr) | 2011-02-25 | 2014-03-01 | Irm Llc | Composes et compositions en tant qu inibiteurs de trk |
| GB201212081D0 (en) * | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2064336B (en) | 1979-12-06 | 1984-03-14 | Glaxo Group Ltd | Device for dispensing medicaments |
| US4353656A (en) * | 1980-10-14 | 1982-10-12 | Xerox Corporation | Moving coil, multiple energy print hammer system including a closed loop servo |
| DE3274065D1 (de) | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
| GB2129691B (en) | 1982-10-08 | 1987-08-05 | Glaxo Group Ltd | Devices for administering medicaments to patients |
| US4778054A (en) * | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
| AU591152B2 (en) * | 1985-07-30 | 1989-11-30 | Glaxo Group Limited | Devices for administering medicaments to patients |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| US5552438A (en) * | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| US5495054A (en) * | 1994-05-31 | 1996-02-27 | Sepracor, Inc. | Tetrahydroindeno[1,2-D][1,3,2]oxazaboroles and their use as enantioselective catalysts |
| US6040344A (en) * | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| GB9700226D0 (en) * | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
| OA11558A (en) * | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| US6632666B2 (en) * | 2000-01-14 | 2003-10-14 | Biolife Solutions, Inc. | Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| AR040661A1 (es) * | 2002-07-26 | 2005-04-13 | Theravance Inc | Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2 |
| JP2006503108A (ja) | 2002-09-16 | 2006-01-26 | グラクソ グループ リミテッド | ピラゾロ［３，４−ｂ］ピリジン化合物およびそれのホスホジエステラーゼ阻害薬としての使用 |
| TW200510277A (en) | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
-
2005
- 2005-03-30 CA CA002561400A patent/CA2561400A1/en not_active Abandoned
- 2005-03-30 WO PCT/GB2005/001241 patent/WO2005095328A1/en not_active Ceased
- 2005-03-30 EP EP05729685A patent/EP1730104A1/en not_active Withdrawn
- 2005-03-30 AU AU2005227733A patent/AU2005227733A1/en not_active Abandoned
- 2005-03-30 JP JP2007505632A patent/JP2007530652A/ja active Pending
- 2005-03-30 BR BRPI0509382-1A patent/BRPI0509382A/pt not_active IP Right Cessation
- 2005-03-30 US US10/599,145 patent/US7846973B2/en not_active Expired - Fee Related
- 2005-03-31 PE PE2005000372A patent/PE20060678A1/es not_active Application Discontinuation
- 2005-03-31 TW TW094110351A patent/TW200536814A/zh unknown
- 2005-03-31 AR ARP050101278A patent/AR052301A1/es not_active Application Discontinuation
-
2006
- 2006-09-13 IL IL178064A patent/IL178064A0/en unknown
- 2006-10-26 NO NO20064884A patent/NO20064884L/no not_active Application Discontinuation
- 2006-10-30 MA MA29421A patent/MA28558B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1730104A1 (en) | 2006-12-13 |
| CA2561400A1 (en) | 2005-10-13 |
| AU2005227733A1 (en) | 2005-10-13 |
| KR20070000508A (ko) | 2007-01-02 |
| IL178064A0 (en) | 2006-12-31 |
| BRPI0509382A (pt) | 2007-09-18 |
| US7846973B2 (en) | 2010-12-07 |
| NO20064884L (no) | 2006-10-26 |
| JP2007530652A (ja) | 2007-11-01 |
| MA28558B1 (fr) | 2007-04-03 |
| AR052301A1 (es) | 2007-03-14 |
| WO2005095328A1 (en) | 2005-10-13 |
| US20100063157A1 (en) | 2010-03-11 |
| TW200536814A (en) | 2005-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0201437A (pt) | Processo para preparar derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-substituìdos" | |
| WO2008062905A3 (en) | Heteromonocyclic compound and use thereof | |
| CO6220955A2 (es) | Una composicion farmaceutica que contiene (a) n1-(5-cloropiridin-2-il)-n2-((1s,2r,4s)-4-[dimetilamino)carbonil]-2-{[(5-metil-4,5,6,7-tetrahidrotiazol[5,4-c]piridin-2-il) carbonil] amino} coclohexil)etanodiamida | |
| WO2008131149A3 (en) | Crystal forms of saxagliptin and processes for preparing same | |
| BR112015006341A2 (pt) | compostos, composição farmacêutica, método para tratar condição fibrótica, quantidade terapeuticamente efetiva de composto, de sal farmaceuticamente aceitável deste ou de composição farmacêutica e usos das mesmas e de compostos e/ou composição farmacêutica | |
| PE20060678A1 (es) | Formas cristalinas de derivados de etilamina y procedimiento de preparacion de los mismos | |
| WO2010107807A3 (en) | Compounds for treating inflammation and pain | |
| BRPI0409211A (pt) | composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto | |
| WO2010132757A3 (en) | Antibacterial aminoglycoside analogs | |
| PH12014500065A1 (en) | A new therapeutical composition containing apomorphine as active ingredient | |
| MX2023003332A (es) | Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades. | |
| PE20040767A1 (es) | Derivado hemisulfato de azido citosina cristalino anhidro | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| BRPI0508392A (pt) | materiais e métodos para tratar distúrbios de coagulação | |
| BRPI0712312A2 (pt) | Composto, processo para a produção do mesmo, composição farmacêutica, agente antimicrobiano, agente anti-mrsa, método para a prevenção ou o tratamento de uma doença infecciosa, e, uso do composto | |
| WO2006051314A8 (en) | Guanidine derivatives as inhibitors of ddah | |
| WO2010019203A8 (en) | Antifungal agents | |
| MX2009011818A (es) | Formulaciones de aminoacido n-halogenado con compuestos anti-inflamatorios. | |
| ECSP21093897A (es) | Compuestos y métodos de uso de los mismos como agentes antibacterianos | |
| PE20080923A1 (es) | Forma cristalina polimorfica qalfa de maleato de (r)-5-[2-(5,6-dietil-indan-2-il-amino)-1-hidroxi-etil]-8-hidroxi-1h-quinolin-2-ona | |
| AR068978A1 (es) | N-oxidos de venlafaxina y o-desmetilvenlafaxina como prodrogas | |
| BR112023024037A2 (pt) | Sal farmaceuticamente aceitável de derivado de pirazoloheteroarila, formas cristalinas, composição farmacêutica, usos dos mesmos e métodos para preparar as referidas formas cristalinas e composição farmacêutica | |
| ES2284970T3 (es) | Compuestos amina 1,2- y 1,3-diol y su utilizacion para el tratamiento de alzheimer. | |
| WO2010066909A3 (en) | New inhibitors for treating diseases associated with an excess transport of hyaluronan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |